Results 71 to 80 of about 79,811 (267)

QSAR Modeling on Benzo[<em>c</em>]phenanthridine Analogues as Topoisomerase I Inhibitors and Anti-cancer Agents

Molecules, 2012
Benzo[<em>c</em>]phenanthridine (BCP) derivatives were identified as topoisomerase I (TOP-I) targeting agents with pronounced antitumor activity.
Thi-Ngoc-Phuong Huynh, Thanh-Dao Tran, Quang-Huynh Bui, Khac-Minh Thai   +3 more
doaj   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo, Elena Maria Tosca, Mirjam Crul, Tim Schutte, Lia van Zuijlen, Idris Bahce, Medhat M. Said, Jan Buter, Harmen Huls, Paolo Magni, Imke Bartelink   +10 more
wiley   +1 more source

Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP[10] with Fluorouracil, Floxuridine, and Topoisomerase 1 Poisons [PDF]

, 2010
William H. Gmeiner, William C. Reinhold, Yves Pommier   +2 more
openalex   +1 more source

A pH‐responsive charge‐reversal liposome with enhanced biofilm penetration for multimodal synergistic therapy of bacterial infections

BMEMat, EarlyView.
This study develops a pH‐responsive, charge‐reversal liposome for treating bacterial biofilm infections. With enhanced penetration capability, the liposome effectively delivers antibacterial agents into biofilms. By integrating photodynamic and photothermal therapies with antibiotics, it significantly eradicates biofilms and accelerates bacteria ...
Ruyue Li, Bo Liu, Cheng Wang, Zhencheng Sun, Shuyi Lv, Liang Tian, Minghui Xiao, Qinyang Zheng, Linqi Shi, Chunlei Zhu   +9 more
wiley   +1 more source

Artemisinin Derivatives Target Topoisomerase 1 and Cause DNA Damage in Silico and in Vitro

Frontiers in Pharmacology, 2017
DNA topoisomerases 1 and 2 are enzymes that maintain DNA topology and play important essential genome functions, including DNA replication and transcription.
Onat Kadioglu, Ariel Chan, Alena Cong Ling Qiu, Vincent Kam Wai Wong, Vanessa Colligs, Sabine Wecklein, Halima Freund-Henni Rached, Thomas Efferth, Wen-Luan Wendy Hsiao   +8 more
doaj   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Clinical Pharmacology &Therapeutics, EarlyView.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, Timothy A. Yap, Ruth Plummer, Anthony W. Tolcher, Johann S. de Bono, Ioannis Gounaris, Zoltan Szucs, Astrid Zimmermann, Irina Kareva, Jayaprakasam Bolleddula, Annick Seithel‐Keuth, Giuseppe Locatelli, Marta Enderlin, Christine Hicking, Anup Zutshi, Wei Gao, Rainer Strotmann, Lisa Benincosa, Karthik Venkatakrishnan   +20 more
wiley   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, EarlyView.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

Nutritionally physiological cell culture medium and 3D culture influence breast tumour proteomics and anti-cancer drug effectiveness

Pharmacological Research
Many drugs have been discontinued during phase II/III breast cancer clinical trials due to lack of clinical efficacy, indicating shortcomings in predictive value of preclinical data.
Xiaodan Zhang, Tianhong Cheng, Ellie Cho, Wenjia Lu, Delphine Denoyer, Paul McMillan, Kalyan Shobhana, Swati Varshney, Nicholas A. Williamson, Alastair Stewart   +9 more
doaj   +1 more source

Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors [PDF]

, 2019
Roxana M. Rodríguez Stewart, Jameson Berry, Angela K. Berger, Sung Bo Yoon, Jaime A. Guberman, Nirav Patel, Gregory K. Tharp, Steven E. Bosinger, Bernardo A. Mainou   +8 more
openalex   +1 more source